Industry weighs radical shake-up of European drug pricing
Wholesale adoption of the concept of drug pricing based on clinical results is proposed
London
THE pharmaceutical industry is considering a radical shift in the way it prices drugs in Europe so companies are rewarded for the clinical benefit of treatments rather than the number of pills sold, according to an internal report.
The high price of drugs is straining Europe's cash-strapped health systems and depriving some patients of the latest products, to the concern of manufacturers who argue they can save costs in the long run by keeping people out of hospital.
TRENDING NOW
Singapore identifies 7 firms responsible for haze fires, notices issued urging action: Grace Fu
Philippine power giant First Gen rebuffs foreign offers, plans up to US$2.6 billion in expansion
DBS remains analysts’ pick ahead of Q3 earnings after Singapore banks’ share slump
Indonesia imposes US$116 million in fines over manipulation of Sinar Mas, Prajogo-linked stocks
